MHRA
- Local brand name: Rhucin
- Status: approved
recombinant human C1 inhibitor (recombinant human C1 inhibitor) regulatory status in United Kingdom.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MHRA has authorised it.
Pharming Technologies B.V. is the originator. The local marketing authorisation holder may differ — check the official source linked above.